B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation

Transplantation

Volumn 85, Issue 3, 2008, Pages 386-390

  Iori, Anna P ^a,c   Torelli, Giovanni F ^a   De Propris, Maria S ^a   Milano, Filippo ^a   Pupella, Simonetta ^a   Gozzer, Maria ^a   Mancini, Francesca ^a   Milani, Maria L ^a   Intoppa, Stefania ^a   Cerretti, Raffaella ^b   Lucarelli, Barbarella ^a   Valle, Veronica ^a   Malandruccolo, Luigi ^a   Iannella, Emilia ^a   Arleo, Eva ^a   Guarini, Anna ^a   Foà, Robin ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c Division of Hematology   (Italy)

Author keywords

Allogeneic stem cell transplantation; B cells; Graft versus host disease; Hematologic malignancies; Prognostic factors

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FOLINIC ACID; LEUKOCYTE ANTIGEN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; APHERESIS; ARTICLE; B LYMPHOCYTE; CELL COMPOSITION; CONTROLLED STUDY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MORTALITY; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; PRIORITY JOURNAL; SCHOOL CHILD;

ACUTE DISEASE; ADOLESCENT; ADULT; B-LYMPHOCYTES; CHILD; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 40049096169     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181622e36     Document Type: Article

References (32)

1. Urbano-Ispizua A, Schmitz N, De Witte T, et al. for the European Group for Blood and Marrow Transplantation. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Definitions and current practice in Europe. Bone Marrow Transplant 2002; 29: 639.
2. Schmitz N, Barrett J. Optimizing engraftment-source and dose of stem cells. Sem Hematol 2002; 39: 3.
3. Gratwohl A, Schmid O, Baldomero H, et al. Accreditation Committee of the European Group for Blood and Marrow Transplantation. Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey. Bone Marrow Transplant 2004; 34: 855.
4. Perez-Simon JA, Diez-Campelo M, Martino R, et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood 2003; 102: 110.
5. Panse JP, Heimfeld S, Guthrie KA, et al. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. Br J Haematol 2005; 128: 659.
6. Baron F, Maris MB, Storer BE, et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after non myeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005; 19: 82.
7. Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221.
8. Mohty M, Bilger K, Jourdan E, et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003; 17: 1467.
9. Zhang C, Todorov I, Zhang Z, et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006; 107: 2993.
10. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapyrefractory chronic graft-versus-host disease. Blood 2004; 104: 2603.
11. Okamoto M, Okano A, Akamatsu S, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006; 20: 172.
12. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108: 756.
13. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with Rituximab: a GITMO study. BMT 2007; 4: 1.
14. Kamble R, Oholendt M, Carrum G. Rituximab responsive refractory acute graft-versus-host-disease. Biol Blood Marrow Transplant 2006; 12: 1201.
15. De Fabritiis P, Iori AP, Mengarelli A, et al. CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G-CSF. Transfusion 2001; 41: 190.
16. Mengarelli A, Iori AP, Romano A, et al. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Haematologica 2003; 88: 315.
17. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukaemia. N Engl J Med 1986; 314: 729.
18. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched siblings donors. Transplantation 1974; 18: 295.
19. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457.
21. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representation of old estimator. Stat Med 1999; 18: 695.
22. Conover WJ. Practical non-parametric statistics. 2nd ed. John Wiley & Sons: New York; 1980.
23. Ringden O, Barrett J, Zhang M-J, et al. Decreased treatment failure in recipients of HLA identical bone marrow or peripheral blood stem cell transplants with high CD34+ cell doses. Br J Haematol 2003; 121: 874.
24. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005; 105: 2973.
25. Tayebi H, Lapierre V, Saas P, et al. Enhanced activation of B cells in a granulocyte colony-stimulating factor-mobilized peripheral blood stem cell graft. Br J Haematol 2001; 114: 698.
26. Korbling M, Huh YO, Durett A, et al. Allogeneic blood stem cell transplantation peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-Idim) and lymphoid subsets, and possible predictors of engraftment and graft versus host disease. Blood 1995; 86: 2842.
27. Cao TM, Wong RM, Sheehan K, et al. CD34, CD4 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for haematological malignancies. Exp Hematol 2005; 33: 279.
28. Urbano-Ispizua A, Rozman C, Pimentel P, et al. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA identical siblings. Blood 2002; 100: 724.
29. Kernan NA, Collins NH, Juliano L, et al. Clonable T lymphocytes in T-cell-depleted bone marrow transplants correlate with development of graft-versus-host disease. Blood 1986; 68: 770.
30. Yamasaki S, Henzan H, Ohno Y, et al. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors. Bone Marrow Transplant 2003; 32: 505.
31. Handgretinger R, Lang P, Klingebiel T, Niethammer D. CD34 stem cell dose and development of extensive chronic graft-versus-host disease. Blood 2002; 99: 3875.
32. Heimfeld S. HLA-identical stem cell transplantation: Is there an optimal CD34 cell dose? Bone Marrow Transplant 2003; 31: 839.